These innovative compounds represent a significant leap in the management of type 2 diabetes. Retatrutide, a combined GLP-1 and GIP receptor agonist, demonstrates exceptional efficacy in lowering blood glucose levels. Trizepatide, on the other hand, targets all three incretin receptors – GLP-1, GIP, and glucagon – leading to a additive effect.